|Bid||12.68 x 1100|
|Ask||12.90 x 1400|
|Day's Range||12.30 - 13.03|
|52 Week Range||5.06 - 14.34|
|Beta (5Y Monthly)||2.05|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 02, 2022 - Aug 08, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||16.38|
Subscribe to Yahoo Finance Plus to view Fair Value for EOLS
Needham initiated coverage on Evolus Inc (NASDAQ: EOLS) with a price target of $18.00 (43% upside) and a Buy rating. Evolus is a pure-play aesthetics company focused on growing the presence of Jeuveau, its new neurotoxin product, in the approximately $3 billion global wrinkle treatment market. Jeuveau is a prescription medicine injected into muscles to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines). Needham views Evolus as an emerging star in aesthetics
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...
The mean of analysts' price targets for Evolus, Inc. (EOLS) points to a 28.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.